limbs/digits/tail
|
• mice develop ringtail
|
growth/size/body
|
• mice are small
|
immune system
|
• mice produce elevated levels of GM-CSF (granulocyte monocyte colony stimulating factor), MIP-2 (macrophage-inflammatory protein-2), GCP-2 (granulocyte chemotactic protein) and MCP-3 (monocyte chemotactic protein-3)
|
|
• mice develop skin inflammation with infiltrate composed of neutrophils, macrophages and lymphocytes
• mice exhibit increased immunoreactivity for markers of keratinocyte hyperproliferation, macrophages, epidermal Langerhans and dermal dendritic cells, inflammation, and T lymphocytes
• peak inflammatory response occurs at P7 and resolves by P21
• however, immune infiltrate can be reduced by treatment with anti-TNF-alpha or anti-Gr1 antibodies
• while treatment with anti-Gr1 antibodies reduced the number of infiltrating neutrophils it does not eliminate them
mice exhibit an increase in CD3+ T lymphocytes in the skin compared to wild-type mice
|
homeostasis/metabolism
|
• mice produce elevated levels of GM-CSF (granulocyte monocyte colony stimulating factor), MIP-2 (macrophage-inflammatory protein-2), GCP-2 (granulocyte chemotactic protein) and MCP-3 (monocyte chemotactic protein-3)
|
integument
|
• mice develop skin inflammation with infiltrate composed of neutrophils, macrophages and lymphocytes
• mice exhibit increased immunoreactivity for markers of keratinocyte hyperproliferation, macrophages, epidermal Langerhans and dermal dendritic cells, inflammation, and T lymphocytes
• peak inflammatory response occurs at P7 and resolves by P21
• however, immune infiltrate can be reduced by treatment with anti-TNF-alpha or anti-Gr1 antibodies
• while treatment with anti-Gr1 antibodies reduced the number of infiltrating neutrophils it does not eliminate them
mice exhibit an increase in CD3+ T lymphocytes in the skin compared to wild-type mice
|
acanthosis
(
J:126327
)
|
• while wild-type mice epidermis decreases in thickness between P1 and P21, mice exhibit increased epidermal thickness with the maximal difference at P5
• however, epidermal thickness can be reduced by treatment with anti-TNF-alpha antibodies
|
flaky skin
(
J:126327
)
skin lesions
(
J:126327
)
|
• recurrence of skin lesions on the face, snout and ears develops at 6 month of age
|


Analysis Tools